5J30 Stock Chart & Stats
€0.04
<€0.01(5.00%)
At close: 4:00 PM EST
€0.04
<€0.01(5.00%)
Day’s Range― - ―
52-Week Range€0.25 - €4.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€17.38M
Enterprise Value€318.37M
Total Cash (Recent Filing)€37.15M
Total Debt (Recent Filing)€23.21M
Price to Earnings (P/E)―
Beta15.60
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.91
Shares Outstanding14,059,788
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.71
Revenue Forecast (FY)€5.91M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthThe return to meaningful revenue growth after a low-growth 2025 indicates improving commercial traction for the Nevisense platform. If sustained, a larger installed and usage base can provide more operating leverage and create a stronger foundation for reaching profitability over the next several quarters.
Solid Gross MarginA gross margin near 59% shows that the company retains meaningful economics after producing or delivering its diagnostic solution. Maintaining this level as revenue scales would help fund commercial expansion and provide leverage for fixed-cost absorption, even though current operating expenses remain too high.
Currently Moderate LeverageThe current leverage profile is materially more manageable than the company’s prior balance-sheet position, with debt contained relative to assets. This gives SciBase some financial flexibility while it scales, although the benefit depends on controlling losses so equity does not weaken again.
Bears Say
Persistent Deep LossesThe scale of current losses shows that the cost base remains far ahead of the company’s revenue base despite improving sales. Persistent operating deficits can delay self-funded growth, consume equity, and make future profitability dependent on substantial scale gains or difficult cost reductions.
Heavy Cash BurnNegative operating and free cash flow across every reported period indicates that SciBase is not yet converting its business into internally generated funding. Continued cash burn can restrict investment choices and increase reliance on external capital until revenue growth and cost control improve materially.
Balance-Sheet Volatility And Funding RiskThe sharp change from very high 2025 leverage to moderate TTM leverage demonstrates that the balance sheet remains sensitive to equity movements and operating performance. If large losses persist, renewed equity pressure could increase financing needs and raise dilution or funding risk.
5J30 FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was €0.25 and its highest was €4.22 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is €17.38M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Nov 12, 2026 which is in 30 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Aug 19, 2026. The company reported -€0.24 earnings per share for the quarter.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 14,059,788 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -€0.24 in its last earnings report. Following the earnings report the stock price went down -2.113%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in DE:5J30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.